Wordt geladen...
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
Most B-cell malignancies express CD19, and a majority of patients with B-cell malignancies are not cured by current standard therapies. Chimeric antigen receptors (CARs) are fusion proteins consisting of antigen recognition moieties and T-cell activation domains. T cells can be genetically modified...
Bewaard in:
| Gepubliceerd in: | Nat Rev Clin Oncol |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6322669/ https://ncbi.nlm.nih.gov/pubmed/23546520 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrclinonc.2013.46 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|